HCW Biologics Inc.
About HCW Biologics Inc.
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing first-in-class immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The company focuses on proprietary immunotherapeutics that target the link between chronic low-grade inflammation and conditions such as autoimmune disorders and cancer. It is advancing candidates including HCW9302 for Phase 1 clinical trials in autoimmune disorders and Immune-Cell Engagers for potential licensing.
- 🔗 HCW Biologics Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results - HCW Biologics, Inc.
- 🔗 HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - HCW Biologics, Inc.
- 🔗 HCW Biologics Inc. Completes $56.0 Million Initial Public Offering
- 🔗 HCW Biologics Inc
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Closed $1.5 million private placement in September 2026.
- Completed $5 million equity offering in May 2025 with a single institutional investor to fund Phase 1 trial sites for HCW9302.
- Formed joint venture Trimmune with WY Biotech for development in China.
- Publicly traded on NASDAQ as HCWB after $56 million IPO.
Ask StreetZero about HCW Biologics Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account